We provide you with 20 years of free, institutional-grade data for CVKD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CVKD. Explore the full financial landscape of CVKD stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about CVKD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Cadrenal Therapeutics(NASDAQ:CVKD) 
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fib...
Website: https://www.cadrenal.com/
Founded: 2022
IPO Price: $5 (Jan 20, 2023)
Full Time Employees: 1
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends